UK’s Revamped Clinical Trials Framework To Offer Faster Application Review Timelines Than EU

Changes Represent Biggest Overhaul In UK Clinical Trials Regulation In Over 20 Years

The UK has finalized plans for delivering what it believes will be a stable and streamlined clinical trials framework following its departure from the EU. Transparency, patient involvement and diversity are high on the agenda.

United Kingdom (UK) science development concept - microscope on flag background.
UK Is Keen To Attract More Clinical Trial Activity • Source: Shutterstock

The UK government has announced much-awaited reforms to its clinical trials framework, explaining how several existing provisions will be soon replaced with new legislation or guidance. The changes, the government says, will make it faster and easier to gain approval and to run clinical trials in the country.

More from United Kingdom

UK’s MHRA To Offer Private Meetings For Innovative RWE Strategies

 

The MHRA’s new scientific dialog program will offer drug developers “closed-door meetings” that will offer “confidential, commercially sensitive discussion” with its staff to help them “refine” their real-world evidence generation strategies.

MHRA: New UK Point Of Care Legislation Will Remove ‘Regulatory Barriers’ To Innovation

 

The UK’s “world-first” tailored regulatory framework for point of care manufacturing is set to enter into force this summer.

UK’s Rare Therapies Launch Pad To Be ‘Fully Operational’ By Year-End

 

“Significant progress” has been made in setting up the UK’s Rare Therapies Launch Pad pilot scheme, which will construct a “new regulatory pathway tailored specifically for ultra-rare diseases,” a senior scientist involved in the project says.

UK Clinical Trial Reforms Pass ‘Major Milestone’

 

New regulations on clinical trials should help the UK remain a popular destination for multinational trials, according to the MHRA, the country’s medicines regulator.

More from Europe

EMA’s Conflict Of Interest Rules Must Not Limit Access To Experts And Risk Innovation, Warns Industry

 

The European Medicines Agency has published new policies on handling conflicts of interests for its scientific committee members, experts and management board members.

UK’s MHRA To Offer Private Meetings For Innovative RWE Strategies

 

The MHRA’s new scientific dialog program will offer drug developers “closed-door meetings” that will offer “confidential, commercially sensitive discussion” with its staff to help them “refine” their real-world evidence generation strategies.

EU Pharma Reform & Reducing Reliance On Asian Imports: What To Expect in 2025

 

The European Commission's 100-day countdown to deliver a Critical Medicines Act, aimed at improving the EU's resilience to supply chain disruptions and price volatility, began last December. Meanwhile, negotiations over the proposed package that will reform the over 20-year-old EU pharmaceutical legislation are now in the hands of the Council of the EU. The Pink Sheet examines what to expect for these key pieces of legislation this year.